Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
At prespecified 104-week time point, semaglutide was associated with lesser decline in eGFR than placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.